VolitionRX Ltd (NYSEAMERICAN:VNRX) major shareholder Corp Ltd Eight sold 46,238 shares of VolitionRX stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $6.03, for a total value of $278,815.14. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of NYSEAMERICAN:VNRX traded down $0.12 during trading on Wednesday, hitting $5.42. 1,900 shares of the stock were exchanged, compared to its average volume of 128,688. VolitionRX Ltd has a 1-year low of $1.67 and a 1-year high of $6.84.
VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Monday, August 12th. The medical research company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Featured Article: Trade War
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.